Form 4: Keros Therapeutics Director Acquires 10,000 Stock Options

Mary Ann Gray, a director of Keros Therapeutics, acquired 10,000 stock options on May 30, 2024, at an exercise price of $46.31.

Summary

• On May 30, 2024, Mary Ann Gray, a director of Keros Therapeutics, acquired 10,000 stock options.
• The exercise price of these options is $46.31.
• The options vest in equal quarterly installments over the 12 months following the grant date, but will be fully vested by the date of the Issuer's 2025 annual meeting of stockholders, provided the Reporting Person continues to provide service.
• Following the transaction, Ms. Gray directly owns 10,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, it's a routine part of executive compensation.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholders, as it may signal confidence in the company's future prospects.

Key Dates